nodes	percent_of_prediction	percent_of_DWPC	metapath
Pentamidine—CYP1A1—Clobetasol propionate—psoriasis	0.0921	0.133	CbGbCtD
Pentamidine—CYP4A11—Dexamethasone—psoriasis	0.0761	0.11	CbGbCtD
Pentamidine—CYP1A1—Methoxsalen—psoriasis	0.0484	0.0699	CbGbCtD
Pentamidine—CYP2C8—Tazarotene—psoriasis	0.0433	0.0626	CbGbCtD
Pentamidine—CYP3A5—Beclomethasone—psoriasis	0.0419	0.0605	CbGbCtD
Pentamidine—CYP1A2—Clobetasol propionate—psoriasis	0.0412	0.0594	CbGbCtD
Pentamidine—CYP1A1—Cholecalciferol—psoriasis	0.0321	0.0463	CbGbCtD
Pentamidine—CYP1A2—Methoxsalen—psoriasis	0.0216	0.0312	CbGbCtD
Pentamidine—CYP2D6—Hydroxyurea—psoriasis	0.0195	0.0281	CbGbCtD
Pentamidine—CYP2C8—Cholecalciferol—psoriasis	0.0185	0.0267	CbGbCtD
Pentamidine—CYP3A5—Mycophenolate mofetil—psoriasis	0.0167	0.0241	CbGbCtD
Pentamidine—CYP2C8—Mycophenolate mofetil—psoriasis	0.016	0.0232	CbGbCtD
Pentamidine—CYP2C19—Cholecalciferol—psoriasis	0.0155	0.0224	CbGbCtD
Pentamidine—CYP3A4—Calcitriol—psoriasis	0.0146	0.021	CbGbCtD
Pentamidine—CYP1A1—Dexamethasone—psoriasis	0.0139	0.02	CbGbCtD
Pentamidine—CYP3A5—Hydrocortisone—psoriasis	0.0134	0.0193	CbGbCtD
Pentamidine—CYP2C8—Hydrocortisone—psoriasis	0.0129	0.0186	CbGbCtD
Pentamidine—CYP3A5—Cyclosporine—psoriasis	0.0126	0.0183	CbGbCtD
Pentamidine—CYP2C8—Cyclosporine—psoriasis	0.0122	0.0176	CbGbCtD
Pentamidine—CYP2D6—Cholecalciferol—psoriasis	0.0118	0.017	CbGbCtD
Pentamidine—CYP3A4—Methoxsalen—psoriasis	0.0113	0.0164	CbGbCtD
Pentamidine—CYP2C19—Prednisone—psoriasis	0.0108	0.0155	CbGbCtD
Pentamidine—CYP2C19—Cyclosporine—psoriasis	0.0102	0.0147	CbGbCtD
Pentamidine—CYP3A5—Dexamethasone—psoriasis	0.00833	0.012	CbGbCtD
Pentamidine—CYP2C8—Dexamethasone—psoriasis	0.008	0.0116	CbGbCtD
Pentamidine—CYP2D6—Cyclosporine—psoriasis	0.00775	0.0112	CbGbCtD
Pentamidine—CYP3A4—Cholecalciferol—psoriasis	0.0075	0.0108	CbGbCtD
Pentamidine—CYP2C19—Dexamethasone—psoriasis	0.00672	0.0097	CbGbCtD
Pentamidine—CYP3A4—Mycophenolate mofetil—psoriasis	0.0065	0.00939	CbGbCtD
Pentamidine—CYP3A4—Triamcinolone—psoriasis	0.0065	0.00939	CbGbCtD
Pentamidine—CYP3A4—Betamethasone—psoriasis	0.00558	0.00806	CbGbCtD
Pentamidine—CYP3A4—Prednisolone—psoriasis	0.00551	0.00795	CbGbCtD
Pentamidine—CYP3A4—Hydrocortisone—psoriasis	0.00522	0.00754	CbGbCtD
Pentamidine—CYP3A4—Prednisone—psoriasis	0.0052	0.00751	CbGbCtD
Pentamidine—S100B—vertebral column—psoriasis	0.00515	0.733	CbGeAlD
Pentamidine—CYP2D6—Dexamethasone—psoriasis	0.00511	0.00737	CbGbCtD
Pentamidine—CYP3A4—Cyclosporine—psoriasis	0.00493	0.00712	CbGbCtD
Pentamidine—CYP3A4—Dexamethasone—psoriasis	0.00325	0.00469	CbGbCtD
Pentamidine—S100B—skin of body—psoriasis	0.000978	0.139	CbGeAlD
Pentamidine—CYP1A1—skin epidermis—psoriasis	0.000682	0.0972	CbGeAlD
Pentamidine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000428	0.00513	CbGpPWpGaD
Pentamidine—S100B—Toll Like Receptor 4 (TLR4) Cascade—SOCS1—psoriasis	0.000426	0.00509	CbGpPWpGaD
Pentamidine—CYP1A1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000424	0.00508	CbGpPWpGaD
Pentamidine—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000423	0.00506	CbGpPWpGaD
Pentamidine—CYP4A11—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000422	0.00505	CbGpPWpGaD
Pentamidine—S100B—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—NFKBIA—psoriasis	0.00041	0.00491	CbGpPWpGaD
Pentamidine—CYP4A11—PPARA activates gene expression—CARM1—psoriasis	0.000397	0.00475	CbGpPWpGaD
Pentamidine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000394	0.00471	CbGpPWpGaD
Pentamidine—S100B—MyD88 cascade initiated on plasma membrane—NFKBIA—psoriasis	0.000391	0.00468	CbGpPWpGaD
Pentamidine—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000389	0.00465	CbGpPWpGaD
Pentamidine—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000389	0.00465	CbGpPWpGaD
Pentamidine—CYP4A11—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000388	0.00464	CbGpPWpGaD
Pentamidine—S100B—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NFKBIA—psoriasis	0.000387	0.00463	CbGpPWpGaD
Pentamidine—S100B—MyD88 dependent cascade initiated on endosome—NFKBIA—psoriasis	0.00038	0.00455	CbGpPWpGaD
Pentamidine—S100B—Toll-Like Receptors Cascades—SOCS1—psoriasis	0.000379	0.00454	CbGpPWpGaD
Pentamidine—S100B—Toll Like Receptor 9 (TLR9) Cascade—NFKBIA—psoriasis	0.000367	0.00439	CbGpPWpGaD
Pentamidine—S100B—MyD88:Mal cascade initiated on plasma membrane—NFKBIA—psoriasis	0.000361	0.00431	CbGpPWpGaD
Pentamidine—S100B—TRAF6 Mediated Induction of proinflammatory cytokines—TYK2—psoriasis	0.000354	0.00423	CbGpPWpGaD
Pentamidine—S100B—Immune System—KIR2DS1—psoriasis	0.000351	0.0042	CbGpPWpGaD
Pentamidine—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000347	0.00415	CbGpPWpGaD
Pentamidine—S100B—MyD88-independent cascade—NFKBIA—psoriasis	0.000346	0.00414	CbGpPWpGaD
Pentamidine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000334	0.00399	CbGpPWpGaD
Pentamidine—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000329	0.00394	CbGpPWpGaD
Pentamidine—S100B—MyD88 cascade initiated on plasma membrane—TYK2—psoriasis	0.00032	0.00383	CbGpPWpGaD
Pentamidine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000319	0.00382	CbGpPWpGaD
Pentamidine—S100B—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—TYK2—psoriasis	0.000317	0.00379	CbGpPWpGaD
Pentamidine—CYP4A11—NRF2 pathway—TGFA—psoriasis	0.000316	0.00378	CbGpPWpGaD
Pentamidine—S100B—MyD88 dependent cascade initiated on endosome—TYK2—psoriasis	0.000311	0.00373	CbGpPWpGaD
Pentamidine—S100B—Activated TLR4 signalling—NFKBIA—psoriasis	0.000311	0.00372	CbGpPWpGaD
Pentamidine—S100B—Cytosolic sensors of pathogen-associated DNA—NFKB1—psoriasis	0.000305	0.00365	CbGpPWpGaD
Pentamidine—S100B—Toll Like Receptor 9 (TLR9) Cascade—TYK2—psoriasis	0.0003	0.0036	CbGpPWpGaD
Pentamidine—S100B—MyD88:Mal cascade initiated on plasma membrane—TYK2—psoriasis	0.000295	0.00353	CbGpPWpGaD
Pentamidine—S100B—Toll Like Receptor 4 (TLR4) Cascade—NFKBIA—psoriasis	0.000293	0.0035	CbGpPWpGaD
Pentamidine—S100B—TRAF6 Mediated Induction of proinflammatory cytokines—JUN—psoriasis	0.000286	0.00343	CbGpPWpGaD
Pentamidine—S100B—MyD88-independent cascade—TYK2—psoriasis	0.000283	0.00339	CbGpPWpGaD
Pentamidine—S100B—TRAF6 Mediated Induction of proinflammatory cytokines—NFKB1—psoriasis	0.000276	0.0033	CbGpPWpGaD
Pentamidine—CYP1A1—Oxidative Stress—CAT—psoriasis	0.000274	0.00328	CbGpPWpGaD
Pentamidine—S100B—Innate Immune System—DDX58—psoriasis	0.000272	0.00325	CbGpPWpGaD
Pentamidine—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000271	0.00324	CbGpPWpGaD
Pentamidine—CYP4A11—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.000267	0.0032	CbGpPWpGaD
Pentamidine—S100B—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—NFKB1—psoriasis	0.000262	0.00313	CbGpPWpGaD
Pentamidine—S100B—Toll-Like Receptors Cascades—NFKBIA—psoriasis	0.000261	0.00312	CbGpPWpGaD
Pentamidine—S100B—MyD88 cascade initiated on plasma membrane—JUN—psoriasis	0.000259	0.0031	CbGpPWpGaD
Pentamidine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000258	0.00308	CbGpPWpGaD
Pentamidine—S100B—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—JUN—psoriasis	0.000257	0.00307	CbGpPWpGaD
Pentamidine—CYP1A1—Estrogen Receptor Pathway—JUN—psoriasis	0.000257	0.00307	CbGpPWpGaD
Pentamidine—S100B—Activated TLR4 signalling—TYK2—psoriasis	0.000255	0.00305	CbGpPWpGaD
Pentamidine—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000254	0.00304	CbGpPWpGaD
Pentamidine—S100B—MyD88 dependent cascade initiated on endosome—JUN—psoriasis	0.000252	0.00302	CbGpPWpGaD
Pentamidine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000251	0.00301	CbGpPWpGaD
Pentamidine—S100B—MyD88 cascade initiated on plasma membrane—NFKB1—psoriasis	0.000249	0.00298	CbGpPWpGaD
Pentamidine—S100B—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NFKB1—psoriasis	0.000247	0.00296	CbGpPWpGaD
Pentamidine—S100B—Toll Like Receptor 9 (TLR9) Cascade—JUN—psoriasis	0.000243	0.00291	CbGpPWpGaD
Pentamidine—S100B—MyD88 dependent cascade initiated on endosome—NFKB1—psoriasis	0.000243	0.0029	CbGpPWpGaD
Pentamidine—S100B—Toll Like Receptor 4 (TLR4) Cascade—TYK2—psoriasis	0.00024	0.00287	CbGpPWpGaD
Pentamidine—S100B—MyD88:Mal cascade initiated on plasma membrane—JUN—psoriasis	0.000239	0.00286	CbGpPWpGaD
Pentamidine—CYP3A5—Biological oxidations—CYP2S1—psoriasis	0.000239	0.00285	CbGpPWpGaD
Pentamidine—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	0.000235	0.00282	CbGpPWpGaD
Pentamidine—S100B—Toll Like Receptor 9 (TLR9) Cascade—NFKB1—psoriasis	0.000234	0.0028	CbGpPWpGaD
Pentamidine—S100B—MyD88:Mal cascade initiated on plasma membrane—NFKB1—psoriasis	0.00023	0.00275	CbGpPWpGaD
Pentamidine—S100B—MyD88-independent cascade—JUN—psoriasis	0.000229	0.00274	CbGpPWpGaD
Pentamidine—CYP1A1—Biological oxidations—CYP2S1—psoriasis	0.000225	0.0027	CbGpPWpGaD
Pentamidine—CYP1A1—Metapathway biotransformation—CYP2S1—psoriasis	0.000222	0.00266	CbGpPWpGaD
Pentamidine—CYP1A1—Estrogen Receptor Pathway—STAT3—psoriasis	0.000222	0.00266	CbGpPWpGaD
Pentamidine—S100B—MyD88-independent cascade—NFKB1—psoriasis	0.000221	0.00264	CbGpPWpGaD
Pentamidine—CYP1A1—Melatonin metabolism and effects—APOE—psoriasis	0.000219	0.00262	CbGpPWpGaD
Pentamidine—S100B—Toll-Like Receptors Cascades—TYK2—psoriasis	0.000214	0.00255	CbGpPWpGaD
Pentamidine—CYP1A1—skin of body—psoriasis	0.000211	0.0301	CbGeAlD
Pentamidine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000209	0.0025	CbGpPWpGaD
Pentamidine—CYP2C8—Biological oxidations—CYP2S1—psoriasis	0.000207	0.00247	CbGpPWpGaD
Pentamidine—S100B—Activated TLR4 signalling—JUN—psoriasis	0.000206	0.00247	CbGpPWpGaD
Pentamidine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000206	0.00246	CbGpPWpGaD
Pentamidine—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.000204	0.00244	CbGpPWpGaD
Pentamidine—S100B—Signaling by ERBB4—TYK2—psoriasis	0.000201	0.00241	CbGpPWpGaD
Pentamidine—S100B—Activated TLR4 signalling—NFKB1—psoriasis	0.000199	0.00238	CbGpPWpGaD
Pentamidine—CYP1A1—Tryptophan metabolism—CAT—psoriasis	0.000194	0.00233	CbGpPWpGaD
Pentamidine—S100B—Toll Like Receptor 4 (TLR4) Cascade—JUN—psoriasis	0.000194	0.00232	CbGpPWpGaD
Pentamidine—S100B—Innate Immune System—IFIH1—psoriasis	0.000187	0.00224	CbGpPWpGaD
Pentamidine—S100B—Toll Like Receptor 4 (TLR4) Cascade—NFKB1—psoriasis	0.000187	0.00224	CbGpPWpGaD
Pentamidine—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000184	0.00221	CbGpPWpGaD
Pentamidine—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000182	0.00218	CbGpPWpGaD
Pentamidine—S100B—Immune System—ERAP1—psoriasis	0.00018	0.00215	CbGpPWpGaD
Pentamidine—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000179	0.00214	CbGpPWpGaD
Pentamidine—S100B—Innate Immune System—HLA-C—psoriasis	0.000177	0.00212	CbGpPWpGaD
Pentamidine—S100B—Innate Immune System—TNFAIP3—psoriasis	0.000175	0.00209	CbGpPWpGaD
Pentamidine—S100B—TRAF6 Mediated Induction of proinflammatory cytokines—IL6—psoriasis	0.000173	0.00207	CbGpPWpGaD
Pentamidine—S100B—Toll-Like Receptors Cascades—JUN—psoriasis	0.000173	0.00207	CbGpPWpGaD
Pentamidine—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.00017	0.00203	CbGpPWpGaD
Pentamidine—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000167	0.002	CbGpPWpGaD
Pentamidine—S100B—Toll-Like Receptors Cascades—NFKB1—psoriasis	0.000166	0.00199	CbGpPWpGaD
Pentamidine—CYP4A11—PPARA activates gene expression—PPARG—psoriasis	0.000165	0.00198	CbGpPWpGaD
Pentamidine—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000164	0.00197	CbGpPWpGaD
Pentamidine—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000164	0.00196	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—HCAR2—psoriasis	0.000162	0.00193	CbGpPWpGaD
Pentamidine—CYP4A11—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	0.000162	0.00193	CbGpPWpGaD
Pentamidine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.00016	0.00192	CbGpPWpGaD
Pentamidine—S100B—Immune System—DDX58—psoriasis	0.000158	0.00189	CbGpPWpGaD
Pentamidine—CYP1A1—PPARA activates gene expression—CARM1—psoriasis	0.000157	0.00188	CbGpPWpGaD
Pentamidine—S100B—MyD88 cascade initiated on plasma membrane—IL6—psoriasis	0.000157	0.00187	CbGpPWpGaD
Pentamidine—S100B—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—IL6—psoriasis	0.000155	0.00186	CbGpPWpGaD
Pentamidine—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000154	0.00184	CbGpPWpGaD
Pentamidine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000153	0.00183	CbGpPWpGaD
Pentamidine—S100B—MyD88 dependent cascade initiated on endosome—IL6—psoriasis	0.000152	0.00182	CbGpPWpGaD
Pentamidine—S100B—Innate Immune System—HLA-E—psoriasis	0.000147	0.00176	CbGpPWpGaD
Pentamidine—S100B—Toll Like Receptor 9 (TLR9) Cascade—IL6—psoriasis	0.000147	0.00176	CbGpPWpGaD
Pentamidine—S100B—MyD88:Mal cascade initiated on plasma membrane—IL6—psoriasis	0.000144	0.00173	CbGpPWpGaD
Pentamidine—CYP1A2—Biological oxidations—CYP2S1—psoriasis	0.000144	0.00172	CbGpPWpGaD
Pentamidine—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	0.000142	0.0017	CbGpPWpGaD
Pentamidine—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	0.000141	0.00169	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—TAGAP—psoriasis	0.00014	0.00168	CbGpPWpGaD
Pentamidine—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	0.000139	0.00167	CbGpPWpGaD
Pentamidine—S100B—MyD88-independent cascade—IL6—psoriasis	0.000139	0.00166	CbGpPWpGaD
Pentamidine—CYP1A1—Melatonin metabolism and effects—NFKB1—psoriasis	0.00013	0.00156	CbGpPWpGaD
Pentamidine—CYP1A1—Oxidative Stress—NFKB1—psoriasis	0.000126	0.00151	CbGpPWpGaD
Pentamidine—S100B—Activated TLR4 signalling—IL6—psoriasis	0.000125	0.00149	CbGpPWpGaD
Pentamidine—CYP1A2—Tryptophan metabolism—CAT—psoriasis	0.000124	0.00148	CbGpPWpGaD
Pentamidine—S100B—Innate Immune System—SOCS1—psoriasis	0.000123	0.00147	CbGpPWpGaD
Pentamidine—S100B—Immune System—ITGAL—psoriasis	0.00012	0.00143	CbGpPWpGaD
Pentamidine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000118	0.00142	CbGpPWpGaD
Pentamidine—S100B—Toll Like Receptor 4 (TLR4) Cascade—IL6—psoriasis	0.000117	0.0014	CbGpPWpGaD
Pentamidine—CYP4A11—Metabolism—NDUFA5—psoriasis	0.000114	0.00137	CbGpPWpGaD
Pentamidine—S100B—Immune System—REL—psoriasis	0.000112	0.00134	CbGpPWpGaD
Pentamidine—CYP4A11—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	0.000111	0.00133	CbGpPWpGaD
Pentamidine—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000111	0.00133	CbGpPWpGaD
Pentamidine—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.000109	0.00131	CbGpPWpGaD
Pentamidine—S100B—Immune System—IFIH1—psoriasis	0.000109	0.0013	CbGpPWpGaD
Pentamidine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000108	0.00129	CbGpPWpGaD
Pentamidine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000107	0.00128	CbGpPWpGaD
Pentamidine—CYP4A11—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000107	0.00127	CbGpPWpGaD
Pentamidine—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	0.000106	0.00127	CbGpPWpGaD
Pentamidine—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.000106	0.00127	CbGpPWpGaD
Pentamidine—S100B—Innate Immune System—HLA-B—psoriasis	0.000105	0.00125	CbGpPWpGaD
Pentamidine—S100B—Toll-Like Receptors Cascades—IL6—psoriasis	0.000104	0.00125	CbGpPWpGaD
Pentamidine—S100B—Immune System—HLA-C—psoriasis	0.000103	0.00123	CbGpPWpGaD
Pentamidine—S100B—Immune System—TNFAIP3—psoriasis	0.000102	0.00122	CbGpPWpGaD
Pentamidine—S100B—Signaling by ERBB4—IL6—psoriasis	9.83e-05	0.00118	CbGpPWpGaD
Pentamidine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	9.78e-05	0.00117	CbGpPWpGaD
Pentamidine—CYP4A11—Metabolism—CYP2S1—psoriasis	9.71e-05	0.00116	CbGpPWpGaD
Pentamidine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	9.57e-05	0.00115	CbGpPWpGaD
Pentamidine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	9.33e-05	0.00112	CbGpPWpGaD
Pentamidine—S100B—Innate Immune System—CRP—psoriasis	9.26e-05	0.00111	CbGpPWpGaD
Pentamidine—CYP1A1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	8.99e-05	0.00108	CbGpPWpGaD
Pentamidine—S100B—Immune System—HLA-E—psoriasis	8.56e-05	0.00102	CbGpPWpGaD
Pentamidine—S100B—Innate Immune System—NFKBIA—psoriasis	8.44e-05	0.00101	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—CCL20—psoriasis	8.4e-05	0.001	CbGpPWpGaD
Pentamidine—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	8.29e-05	0.000992	CbGpPWpGaD
Pentamidine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.25e-05	0.000987	CbGpPWpGaD
Pentamidine—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	8.16e-05	0.000976	CbGpPWpGaD
Pentamidine—Pain—Mycophenolate mofetil—psoriasis	8.14e-05	0.000375	CcSEcCtD
Pentamidine—Constipation—Mycophenolate mofetil—psoriasis	8.14e-05	0.000375	CcSEcCtD
Pentamidine—Arrhythmia—Prednisone—psoriasis	8.11e-05	0.000374	CcSEcCtD
Pentamidine—Infection—Triamcinolone—psoriasis	8.11e-05	0.000374	CcSEcCtD
Pentamidine—Hypotension—Hydrocortisone—psoriasis	8.1e-05	0.000373	CcSEcCtD
Pentamidine—Haematuria—Methotrexate—psoriasis	8.06e-05	0.000371	CcSEcCtD
Pentamidine—Feeling abnormal—Cyclosporine—psoriasis	8.04e-05	0.00037	CcSEcCtD
Pentamidine—Shock—Triamcinolone—psoriasis	8.03e-05	0.00037	CcSEcCtD
Pentamidine—Insomnia—Prednisolone—psoriasis	8.03e-05	0.00037	CcSEcCtD
Pentamidine—Gastrointestinal pain—Cyclosporine—psoriasis	7.98e-05	0.000368	CcSEcCtD
Pentamidine—Loss of consciousness—Betamethasone—psoriasis	7.98e-05	0.000368	CcSEcCtD
Pentamidine—Loss of consciousness—Dexamethasone—psoriasis	7.98e-05	0.000368	CcSEcCtD
Pentamidine—Dizziness—Mycophenolic acid—psoriasis	7.97e-05	0.000367	CcSEcCtD
Pentamidine—Paraesthesia—Prednisolone—psoriasis	7.97e-05	0.000367	CcSEcCtD
Pentamidine—Tachycardia—Triamcinolone—psoriasis	7.97e-05	0.000367	CcSEcCtD
Pentamidine—Erythema—Prednisone—psoriasis	7.9e-05	0.000364	CcSEcCtD
Pentamidine—Musculoskeletal discomfort—Hydrocortisone—psoriasis	7.9e-05	0.000364	CcSEcCtD
Pentamidine—Convulsion—Dexamethasone—psoriasis	7.86e-05	0.000362	CcSEcCtD
Pentamidine—Convulsion—Betamethasone—psoriasis	7.86e-05	0.000362	CcSEcCtD
Pentamidine—Feeling abnormal—Mycophenolate mofetil—psoriasis	7.84e-05	0.000361	CcSEcCtD
Pentamidine—Insomnia—Hydrocortisone—psoriasis	7.84e-05	0.000361	CcSEcCtD
Pentamidine—Hypertension—Betamethasone—psoriasis	7.83e-05	0.000361	CcSEcCtD
Pentamidine—Hypertension—Dexamethasone—psoriasis	7.83e-05	0.000361	CcSEcCtD
Pentamidine—Paraesthesia—Hydrocortisone—psoriasis	7.78e-05	0.000359	CcSEcCtD
Pentamidine—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	7.78e-05	0.000359	CcSEcCtD
Pentamidine—Urticaria—Cyclosporine—psoriasis	7.75e-05	0.000357	CcSEcCtD
Pentamidine—Myalgia—Betamethasone—psoriasis	7.73e-05	0.000356	CcSEcCtD
Pentamidine—Myalgia—Dexamethasone—psoriasis	7.73e-05	0.000356	CcSEcCtD
Pentamidine—Abdominal pain—Cyclosporine—psoriasis	7.71e-05	0.000355	CcSEcCtD
Pentamidine—Body temperature increased—Cyclosporine—psoriasis	7.71e-05	0.000355	CcSEcCtD
Pentamidine—Anxiety—Dexamethasone—psoriasis	7.7e-05	0.000355	CcSEcCtD
Pentamidine—Anxiety—Betamethasone—psoriasis	7.7e-05	0.000355	CcSEcCtD
Pentamidine—Vomiting—Mycophenolic acid—psoriasis	7.67e-05	0.000353	CcSEcCtD
Pentamidine—Discomfort—Dexamethasone—psoriasis	7.63e-05	0.000352	CcSEcCtD
Pentamidine—Discomfort—Betamethasone—psoriasis	7.63e-05	0.000352	CcSEcCtD
Pentamidine—Dyspepsia—Hydrocortisone—psoriasis	7.63e-05	0.000352	CcSEcCtD
Pentamidine—Rash—Mycophenolic acid—psoriasis	7.6e-05	0.00035	CcSEcCtD
Pentamidine—Dermatitis—Mycophenolic acid—psoriasis	7.6e-05	0.00035	CcSEcCtD
Pentamidine—Pain—Prednisolone—psoriasis	7.59e-05	0.00035	CcSEcCtD
Pentamidine—Hepatitis—Methotrexate—psoriasis	7.59e-05	0.00035	CcSEcCtD
Pentamidine—Urticaria—Mycophenolate mofetil—psoriasis	7.56e-05	0.000348	CcSEcCtD
Pentamidine—Headache—Mycophenolic acid—psoriasis	7.55e-05	0.000348	CcSEcCtD
Pentamidine—Decreased appetite—Hydrocortisone—psoriasis	7.54e-05	0.000347	CcSEcCtD
Pentamidine—Pharyngitis—Methotrexate—psoriasis	7.53e-05	0.000347	CcSEcCtD
Pentamidine—Abdominal pain—Mycophenolate mofetil—psoriasis	7.52e-05	0.000347	CcSEcCtD
Pentamidine—Body temperature increased—Mycophenolate mofetil—psoriasis	7.52e-05	0.000347	CcSEcCtD
Pentamidine—Fatigue—Hydrocortisone—psoriasis	7.47e-05	0.000344	CcSEcCtD
Pentamidine—Vision blurred—Prednisone—psoriasis	7.45e-05	0.000343	CcSEcCtD
Pentamidine—Musculoskeletal discomfort—Triamcinolone—psoriasis	7.44e-05	0.000343	CcSEcCtD
Pentamidine—Pain—Hydrocortisone—psoriasis	7.41e-05	0.000342	CcSEcCtD
Pentamidine—Anaphylactic shock—Betamethasone—psoriasis	7.41e-05	0.000341	CcSEcCtD
Pentamidine—Anaphylactic shock—Dexamethasone—psoriasis	7.41e-05	0.000341	CcSEcCtD
Pentamidine—Insomnia—Triamcinolone—psoriasis	7.38e-05	0.00034	CcSEcCtD
Pentamidine—Infection—Dexamethasone—psoriasis	7.36e-05	0.000339	CcSEcCtD
Pentamidine—Infection—Betamethasone—psoriasis	7.36e-05	0.000339	CcSEcCtD
Pentamidine—Paraesthesia—Triamcinolone—psoriasis	7.33e-05	0.000338	CcSEcCtD
Pentamidine—Feeling abnormal—Prednisolone—psoriasis	7.31e-05	0.000337	CcSEcCtD
Pentamidine—Anaemia—Prednisone—psoriasis	7.3e-05	0.000337	CcSEcCtD
Pentamidine—Shock—Betamethasone—psoriasis	7.29e-05	0.000336	CcSEcCtD
Pentamidine—Shock—Dexamethasone—psoriasis	7.29e-05	0.000336	CcSEcCtD
Pentamidine—Dyspnoea—Triamcinolone—psoriasis	7.28e-05	0.000335	CcSEcCtD
Pentamidine—Thrombocytopenia—Dexamethasone—psoriasis	7.25e-05	0.000334	CcSEcCtD
Pentamidine—Thrombocytopenia—Betamethasone—psoriasis	7.25e-05	0.000334	CcSEcCtD
Pentamidine—Tachycardia—Dexamethasone—psoriasis	7.23e-05	0.000333	CcSEcCtD
Pentamidine—Tachycardia—Betamethasone—psoriasis	7.23e-05	0.000333	CcSEcCtD
Pentamidine—Angioedema—Prednisone—psoriasis	7.22e-05	0.000333	CcSEcCtD
Pentamidine—Hypersensitivity—Cyclosporine—psoriasis	7.19e-05	0.000331	CcSEcCtD
Pentamidine—Dyspepsia—Triamcinolone—psoriasis	7.18e-05	0.000331	CcSEcCtD
Pentamidine—Erythema multiforme—Methotrexate—psoriasis	7.17e-05	0.000331	CcSEcCtD
Pentamidine—Nausea—Mycophenolic acid—psoriasis	7.16e-05	0.00033	CcSEcCtD
Pentamidine—S100B—Immune System—SOCS1—psoriasis	7.15e-05	0.000856	CbGpPWpGaD
Pentamidine—Feeling abnormal—Hydrocortisone—psoriasis	7.14e-05	0.000329	CcSEcCtD
Pentamidine—Vertigo—Prednisone—psoriasis	7.1e-05	0.000327	CcSEcCtD
Pentamidine—Gastrointestinal pain—Hydrocortisone—psoriasis	7.09e-05	0.000327	CcSEcCtD
Pentamidine—Syncope—Prednisone—psoriasis	7.09e-05	0.000327	CcSEcCtD
Pentamidine—Anorexia—Dexamethasone—psoriasis	7.06e-05	0.000325	CcSEcCtD
Pentamidine—Anorexia—Betamethasone—psoriasis	7.06e-05	0.000325	CcSEcCtD
Pentamidine—Urticaria—Prednisolone—psoriasis	7.05e-05	0.000325	CcSEcCtD
Pentamidine—Fatigue—Triamcinolone—psoriasis	7.04e-05	0.000324	CcSEcCtD
Pentamidine—Hypersensitivity—Mycophenolate mofetil—psoriasis	7.01e-05	0.000323	CcSEcCtD
Pentamidine—Asthenia—Cyclosporine—psoriasis	7e-05	0.000322	CcSEcCtD
Pentamidine—CYP1A1—Aryl Hydrocarbon Receptor—TNF—psoriasis	6.99e-05	0.000836	CbGpPWpGaD
Pentamidine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	6.99e-05	0.000836	CbGpPWpGaD
Pentamidine—Pain—Triamcinolone—psoriasis	6.98e-05	0.000322	CcSEcCtD
Pentamidine—Loss of consciousness—Prednisone—psoriasis	6.95e-05	0.00032	CcSEcCtD
Pentamidine—Hypotension—Betamethasone—psoriasis	6.92e-05	0.000319	CcSEcCtD
Pentamidine—Hypotension—Dexamethasone—psoriasis	6.92e-05	0.000319	CcSEcCtD
Pentamidine—S100B—Innate Immune System—TYK2—psoriasis	6.92e-05	0.000828	CbGpPWpGaD
Pentamidine—Pruritus—Cyclosporine—psoriasis	6.9e-05	0.000318	CcSEcCtD
Pentamidine—Urticaria—Hydrocortisone—psoriasis	6.89e-05	0.000317	CcSEcCtD
Pentamidine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	6.89e-05	0.000824	CbGpPWpGaD
Pentamidine—Body temperature increased—Hydrocortisone—psoriasis	6.85e-05	0.000316	CcSEcCtD
Pentamidine—Abdominal pain—Hydrocortisone—psoriasis	6.85e-05	0.000316	CcSEcCtD
Pentamidine—Convulsion—Prednisone—psoriasis	6.85e-05	0.000316	CcSEcCtD
Pentamidine—Asthenia—Mycophenolate mofetil—psoriasis	6.83e-05	0.000315	CcSEcCtD
Pentamidine—Hypertension—Prednisone—psoriasis	6.82e-05	0.000314	CcSEcCtD
Pentamidine—Chills—Methotrexate—psoriasis	6.81e-05	0.000314	CcSEcCtD
Pentamidine—Musculoskeletal discomfort—Betamethasone—psoriasis	6.75e-05	0.000311	CcSEcCtD
Pentamidine—Musculoskeletal discomfort—Dexamethasone—psoriasis	6.75e-05	0.000311	CcSEcCtD
Pentamidine—Pruritus—Mycophenolate mofetil—psoriasis	6.73e-05	0.00031	CcSEcCtD
Pentamidine—Myalgia—Prednisone—psoriasis	6.73e-05	0.00031	CcSEcCtD
Pentamidine—Arthralgia—Prednisone—psoriasis	6.73e-05	0.00031	CcSEcCtD
Pentamidine—Feeling abnormal—Triamcinolone—psoriasis	6.73e-05	0.00031	CcSEcCtD
Pentamidine—Anxiety—Prednisone—psoriasis	6.7e-05	0.000309	CcSEcCtD
Pentamidine—Insomnia—Dexamethasone—psoriasis	6.7e-05	0.000309	CcSEcCtD
Pentamidine—Insomnia—Betamethasone—psoriasis	6.7e-05	0.000309	CcSEcCtD
Pentamidine—Diarrhoea—Cyclosporine—psoriasis	6.67e-05	0.000308	CcSEcCtD
Pentamidine—Paraesthesia—Dexamethasone—psoriasis	6.65e-05	0.000306	CcSEcCtD
Pentamidine—Paraesthesia—Betamethasone—psoriasis	6.65e-05	0.000306	CcSEcCtD
Pentamidine—Discomfort—Prednisone—psoriasis	6.65e-05	0.000306	CcSEcCtD
Pentamidine—Erythema—Methotrexate—psoriasis	6.6e-05	0.000304	CcSEcCtD
Pentamidine—CYP1A1—PPARA activates gene expression—PPARG—psoriasis	6.55e-05	0.000784	CbGpPWpGaD
Pentamidine—Hypersensitivity—Prednisolone—psoriasis	6.54e-05	0.000301	CcSEcCtD
Pentamidine—Dyspepsia—Betamethasone—psoriasis	6.52e-05	0.0003	CcSEcCtD
Pentamidine—Dyspepsia—Dexamethasone—psoriasis	6.52e-05	0.0003	CcSEcCtD
Pentamidine—Diarrhoea—Mycophenolate mofetil—psoriasis	6.51e-05	0.0003	CcSEcCtD
Pentamidine—Urticaria—Triamcinolone—psoriasis	6.48e-05	0.000299	CcSEcCtD
Pentamidine—Dysgeusia—Methotrexate—psoriasis	6.47e-05	0.000298	CcSEcCtD
Pentamidine—Body temperature increased—Triamcinolone—psoriasis	6.45e-05	0.000297	CcSEcCtD
Pentamidine—Dizziness—Cyclosporine—psoriasis	6.45e-05	0.000297	CcSEcCtD
Pentamidine—Anaphylactic shock—Prednisone—psoriasis	6.45e-05	0.000297	CcSEcCtD
Pentamidine—Decreased appetite—Betamethasone—psoriasis	6.44e-05	0.000297	CcSEcCtD
Pentamidine—Decreased appetite—Dexamethasone—psoriasis	6.44e-05	0.000297	CcSEcCtD
Pentamidine—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	6.41e-05	0.000767	CbGpPWpGaD
Pentamidine—Infection—Prednisone—psoriasis	6.41e-05	0.000295	CcSEcCtD
Pentamidine—Hypersensitivity—Hydrocortisone—psoriasis	6.39e-05	0.000294	CcSEcCtD
Pentamidine—Fatigue—Dexamethasone—psoriasis	6.39e-05	0.000294	CcSEcCtD
Pentamidine—Fatigue—Betamethasone—psoriasis	6.39e-05	0.000294	CcSEcCtD
Pentamidine—Shock—Prednisone—psoriasis	6.35e-05	0.000292	CcSEcCtD
Pentamidine—S100B—Immune System—CD8A—psoriasis	6.34e-05	0.000759	CbGpPWpGaD
Pentamidine—Pain—Betamethasone—psoriasis	6.33e-05	0.000292	CcSEcCtD
Pentamidine—Pain—Dexamethasone—psoriasis	6.33e-05	0.000292	CcSEcCtD
Pentamidine—Tachycardia—Prednisone—psoriasis	6.29e-05	0.00029	CcSEcCtD
Pentamidine—Dizziness—Mycophenolate mofetil—psoriasis	6.29e-05	0.00029	CcSEcCtD
Pentamidine—S100B—Innate Immune System—CD4—psoriasis	6.25e-05	0.000748	CbGpPWpGaD
Pentamidine—Vision blurred—Methotrexate—psoriasis	6.22e-05	0.000287	CcSEcCtD
Pentamidine—Asthenia—Hydrocortisone—psoriasis	6.22e-05	0.000287	CcSEcCtD
Pentamidine—Vomiting—Cyclosporine—psoriasis	6.2e-05	0.000286	CcSEcCtD
Pentamidine—Rash—Cyclosporine—psoriasis	6.15e-05	0.000283	CcSEcCtD
Pentamidine—Anorexia—Prednisone—psoriasis	6.15e-05	0.000283	CcSEcCtD
Pentamidine—Dermatitis—Cyclosporine—psoriasis	6.14e-05	0.000283	CcSEcCtD
Pentamidine—Pruritus—Hydrocortisone—psoriasis	6.13e-05	0.000283	CcSEcCtD
Pentamidine—Headache—Cyclosporine—psoriasis	6.11e-05	0.000282	CcSEcCtD
Pentamidine—Anaemia—Methotrexate—psoriasis	6.1e-05	0.000281	CcSEcCtD
Pentamidine—Feeling abnormal—Betamethasone—psoriasis	6.1e-05	0.000281	CcSEcCtD
Pentamidine—Feeling abnormal—Dexamethasone—psoriasis	6.1e-05	0.000281	CcSEcCtD
Pentamidine—S100B—Immune System—HLA-B—psoriasis	6.1e-05	0.00073	CbGpPWpGaD
Pentamidine—Gastrointestinal pain—Dexamethasone—psoriasis	6.06e-05	0.000279	CcSEcCtD
Pentamidine—Gastrointestinal pain—Betamethasone—psoriasis	6.06e-05	0.000279	CcSEcCtD
Pentamidine—Vomiting—Mycophenolate mofetil—psoriasis	6.05e-05	0.000279	CcSEcCtD
Pentamidine—Hypersensitivity—Triamcinolone—psoriasis	6.01e-05	0.000277	CcSEcCtD
Pentamidine—Rash—Mycophenolate mofetil—psoriasis	6e-05	0.000276	CcSEcCtD
Pentamidine—Dermatitis—Mycophenolate mofetil—psoriasis	5.99e-05	0.000276	CcSEcCtD
Pentamidine—Headache—Mycophenolate mofetil—psoriasis	5.96e-05	0.000275	CcSEcCtD
Pentamidine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	5.95e-05	0.000712	CbGpPWpGaD
Pentamidine—Vertigo—Methotrexate—psoriasis	5.93e-05	0.000273	CcSEcCtD
Pentamidine—Diarrhoea—Hydrocortisone—psoriasis	5.93e-05	0.000273	CcSEcCtD
Pentamidine—Leukopenia—Methotrexate—psoriasis	5.91e-05	0.000272	CcSEcCtD
Pentamidine—Urticaria—Dexamethasone—psoriasis	5.88e-05	0.000271	CcSEcCtD
Pentamidine—Urticaria—Betamethasone—psoriasis	5.88e-05	0.000271	CcSEcCtD
Pentamidine—Musculoskeletal discomfort—Prednisone—psoriasis	5.88e-05	0.000271	CcSEcCtD
Pentamidine—Dizziness—Prednisolone—psoriasis	5.87e-05	0.00027	CcSEcCtD
Pentamidine—Asthenia—Triamcinolone—psoriasis	5.86e-05	0.00027	CcSEcCtD
Pentamidine—Abdominal pain—Dexamethasone—psoriasis	5.85e-05	0.00027	CcSEcCtD
Pentamidine—Body temperature increased—Betamethasone—psoriasis	5.85e-05	0.00027	CcSEcCtD
Pentamidine—Abdominal pain—Betamethasone—psoriasis	5.85e-05	0.00027	CcSEcCtD
Pentamidine—Body temperature increased—Dexamethasone—psoriasis	5.85e-05	0.00027	CcSEcCtD
Pentamidine—Insomnia—Prednisone—psoriasis	5.83e-05	0.000269	CcSEcCtD
Pentamidine—Nausea—Cyclosporine—psoriasis	5.79e-05	0.000267	CcSEcCtD
Pentamidine—Paraesthesia—Prednisone—psoriasis	5.79e-05	0.000267	CcSEcCtD
Pentamidine—Pruritus—Triamcinolone—psoriasis	5.77e-05	0.000266	CcSEcCtD
Pentamidine—Cough—Methotrexate—psoriasis	5.76e-05	0.000266	CcSEcCtD
Pentamidine—Dizziness—Hydrocortisone—psoriasis	5.73e-05	0.000264	CcSEcCtD
Pentamidine—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	5.73e-05	0.000686	CbGpPWpGaD
Pentamidine—Convulsion—Methotrexate—psoriasis	5.72e-05	0.000264	CcSEcCtD
Pentamidine—Dyspepsia—Prednisone—psoriasis	5.68e-05	0.000262	CcSEcCtD
Pentamidine—S100B—Immune System—HLA-A—psoriasis	5.65e-05	0.000676	CbGpPWpGaD
Pentamidine—Nausea—Mycophenolate mofetil—psoriasis	5.65e-05	0.00026	CcSEcCtD
Pentamidine—Chest pain—Methotrexate—psoriasis	5.62e-05	0.000259	CcSEcCtD
Pentamidine—Arthralgia—Methotrexate—psoriasis	5.62e-05	0.000259	CcSEcCtD
Pentamidine—Myalgia—Methotrexate—psoriasis	5.62e-05	0.000259	CcSEcCtD
Pentamidine—Decreased appetite—Prednisone—psoriasis	5.61e-05	0.000258	CcSEcCtD
Pentamidine—S100B—Innate Immune System—JUN—psoriasis	5.6e-05	0.00067	CbGpPWpGaD
Pentamidine—Rash—Prednisolone—psoriasis	5.6e-05	0.000258	CcSEcCtD
Pentamidine—Dermatitis—Prednisolone—psoriasis	5.59e-05	0.000258	CcSEcCtD
Pentamidine—Fatigue—Prednisone—psoriasis	5.56e-05	0.000256	CcSEcCtD
Pentamidine—Headache—Prednisolone—psoriasis	5.56e-05	0.000256	CcSEcCtD
Pentamidine—Discomfort—Methotrexate—psoriasis	5.56e-05	0.000256	CcSEcCtD
Pentamidine—Constipation—Prednisone—psoriasis	5.52e-05	0.000254	CcSEcCtD
Pentamidine—Vomiting—Hydrocortisone—psoriasis	5.51e-05	0.000254	CcSEcCtD
Pentamidine—Rash—Hydrocortisone—psoriasis	5.47e-05	0.000252	CcSEcCtD
Pentamidine—Dermatitis—Hydrocortisone—psoriasis	5.46e-05	0.000252	CcSEcCtD
Pentamidine—Confusional state—Methotrexate—psoriasis	5.44e-05	0.00025	CcSEcCtD
Pentamidine—Headache—Hydrocortisone—psoriasis	5.43e-05	0.00025	CcSEcCtD
Pentamidine—Dizziness—Triamcinolone—psoriasis	5.4e-05	0.000249	CcSEcCtD
Pentamidine—S100B—Immune System—CRP—psoriasis	5.39e-05	0.000645	CbGpPWpGaD
Pentamidine—Anaphylactic shock—Methotrexate—psoriasis	5.39e-05	0.000248	CcSEcCtD
Pentamidine—S100B—Innate Immune System—NFKB1—psoriasis	5.39e-05	0.000645	CbGpPWpGaD
Pentamidine—Infection—Methotrexate—psoriasis	5.36e-05	0.000247	CcSEcCtD
Pentamidine—Feeling abnormal—Prednisone—psoriasis	5.31e-05	0.000245	CcSEcCtD
Pentamidine—Asthenia—Betamethasone—psoriasis	5.31e-05	0.000245	CcSEcCtD
Pentamidine—Asthenia—Dexamethasone—psoriasis	5.31e-05	0.000245	CcSEcCtD
Pentamidine—Thrombocytopenia—Methotrexate—psoriasis	5.28e-05	0.000243	CcSEcCtD
Pentamidine—Gastrointestinal pain—Prednisone—psoriasis	5.27e-05	0.000243	CcSEcCtD
Pentamidine—Nausea—Prednisolone—psoriasis	5.27e-05	0.000243	CcSEcCtD
Pentamidine—Pruritus—Dexamethasone—psoriasis	5.24e-05	0.000241	CcSEcCtD
Pentamidine—Pruritus—Betamethasone—psoriasis	5.24e-05	0.000241	CcSEcCtD
Pentamidine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	5.2e-05	0.000622	CbGpPWpGaD
Pentamidine—Vomiting—Triamcinolone—psoriasis	5.19e-05	0.000239	CcSEcCtD
Pentamidine—S100B—Immune System—HLA-DRB1—psoriasis	5.16e-05	0.000618	CbGpPWpGaD
Pentamidine—Nausea—Hydrocortisone—psoriasis	5.15e-05	0.000237	CcSEcCtD
Pentamidine—Rash—Triamcinolone—psoriasis	5.15e-05	0.000237	CcSEcCtD
Pentamidine—Dermatitis—Triamcinolone—psoriasis	5.14e-05	0.000237	CcSEcCtD
Pentamidine—Anorexia—Methotrexate—psoriasis	5.14e-05	0.000237	CcSEcCtD
Pentamidine—Urticaria—Prednisone—psoriasis	5.12e-05	0.000236	CcSEcCtD
Pentamidine—Headache—Triamcinolone—psoriasis	5.11e-05	0.000236	CcSEcCtD
Pentamidine—Abdominal pain—Prednisone—psoriasis	5.1e-05	0.000235	CcSEcCtD
Pentamidine—Body temperature increased—Prednisone—psoriasis	5.1e-05	0.000235	CcSEcCtD
Pentamidine—CYP4A11—Metabolism of lipids and lipoproteins—APOE—psoriasis	5.09e-05	0.000609	CbGpPWpGaD
Pentamidine—Diarrhoea—Betamethasone—psoriasis	5.07e-05	0.000233	CcSEcCtD
Pentamidine—Diarrhoea—Dexamethasone—psoriasis	5.07e-05	0.000233	CcSEcCtD
Pentamidine—Hypotension—Methotrexate—psoriasis	5.04e-05	0.000232	CcSEcCtD
Pentamidine—S100B—Immune System—ICAM1—psoriasis	4.96e-05	0.000593	CbGpPWpGaD
Pentamidine—S100B—Immune System—NFKBIA—psoriasis	4.92e-05	0.000589	CbGpPWpGaD
Pentamidine—Musculoskeletal discomfort—Methotrexate—psoriasis	4.91e-05	0.000226	CcSEcCtD
Pentamidine—Dizziness—Betamethasone—psoriasis	4.9e-05	0.000226	CcSEcCtD
Pentamidine—Dizziness—Dexamethasone—psoriasis	4.9e-05	0.000226	CcSEcCtD
Pentamidine—Insomnia—Methotrexate—psoriasis	4.88e-05	0.000225	CcSEcCtD
Pentamidine—Nausea—Triamcinolone—psoriasis	4.85e-05	0.000223	CcSEcCtD
Pentamidine—Paraesthesia—Methotrexate—psoriasis	4.84e-05	0.000223	CcSEcCtD
Pentamidine—Dyspnoea—Methotrexate—psoriasis	4.81e-05	0.000221	CcSEcCtD
Pentamidine—CYP3A5—Metabolism—NDUFA5—psoriasis	4.8e-05	0.000574	CbGpPWpGaD
Pentamidine—Somnolence—Methotrexate—psoriasis	4.79e-05	0.000221	CcSEcCtD
Pentamidine—Hypersensitivity—Prednisone—psoriasis	4.75e-05	0.000219	CcSEcCtD
Pentamidine—Dyspepsia—Methotrexate—psoriasis	4.74e-05	0.000219	CcSEcCtD
Pentamidine—CYP4A11—Metabolism—CARM1—psoriasis	4.74e-05	0.000568	CbGpPWpGaD
Pentamidine—Vomiting—Dexamethasone—psoriasis	4.71e-05	0.000217	CcSEcCtD
Pentamidine—Vomiting—Betamethasone—psoriasis	4.71e-05	0.000217	CcSEcCtD
Pentamidine—Decreased appetite—Methotrexate—psoriasis	4.69e-05	0.000216	CcSEcCtD
Pentamidine—Rash—Dexamethasone—psoriasis	4.67e-05	0.000215	CcSEcCtD
Pentamidine—Rash—Betamethasone—psoriasis	4.67e-05	0.000215	CcSEcCtD
Pentamidine—Dermatitis—Dexamethasone—psoriasis	4.67e-05	0.000215	CcSEcCtD
Pentamidine—Dermatitis—Betamethasone—psoriasis	4.67e-05	0.000215	CcSEcCtD
Pentamidine—Fatigue—Methotrexate—psoriasis	4.65e-05	0.000214	CcSEcCtD
Pentamidine—Headache—Dexamethasone—psoriasis	4.64e-05	0.000214	CcSEcCtD
Pentamidine—Headache—Betamethasone—psoriasis	4.64e-05	0.000214	CcSEcCtD
Pentamidine—Asthenia—Prednisone—psoriasis	4.63e-05	0.000213	CcSEcCtD
Pentamidine—S100B—Signaling Pathways—SOCS1—psoriasis	4.62e-05	0.000553	CbGpPWpGaD
Pentamidine—Pain—Methotrexate—psoriasis	4.61e-05	0.000212	CcSEcCtD
Pentamidine—Pruritus—Prednisone—psoriasis	4.56e-05	0.00021	CcSEcCtD
Pentamidine—CYP1A1—Metabolism—NDUFA5—psoriasis	4.53e-05	0.000542	CbGpPWpGaD
Pentamidine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	4.46e-05	0.000533	CbGpPWpGaD
Pentamidine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	4.46e-05	0.000533	CbGpPWpGaD
Pentamidine—Feeling abnormal—Methotrexate—psoriasis	4.44e-05	0.000205	CcSEcCtD
Pentamidine—CYP4A11—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.43e-05	0.000531	CbGpPWpGaD
Pentamidine—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	4.42e-05	0.000529	CbGpPWpGaD
Pentamidine—Diarrhoea—Prednisone—psoriasis	4.41e-05	0.000203	CcSEcCtD
Pentamidine—Gastrointestinal pain—Methotrexate—psoriasis	4.41e-05	0.000203	CcSEcCtD
Pentamidine—Nausea—Betamethasone—psoriasis	4.4e-05	0.000203	CcSEcCtD
Pentamidine—Nausea—Dexamethasone—psoriasis	4.4e-05	0.000203	CcSEcCtD
Pentamidine—Urticaria—Methotrexate—psoriasis	4.28e-05	0.000197	CcSEcCtD
Pentamidine—Dizziness—Prednisone—psoriasis	4.27e-05	0.000197	CcSEcCtD
Pentamidine—Body temperature increased—Methotrexate—psoriasis	4.26e-05	0.000196	CcSEcCtD
Pentamidine—Abdominal pain—Methotrexate—psoriasis	4.26e-05	0.000196	CcSEcCtD
Pentamidine—CYP1A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.23e-05	0.000506	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism—NDUFA5—psoriasis	4.16e-05	0.000497	CbGpPWpGaD
Pentamidine—Vomiting—Prednisone—psoriasis	4.1e-05	0.000189	CcSEcCtD
Pentamidine—CYP3A5—Metabolism—CYP2S1—psoriasis	4.08e-05	0.000488	CbGpPWpGaD
Pentamidine—Rash—Prednisone—psoriasis	4.07e-05	0.000187	CcSEcCtD
Pentamidine—Dermatitis—Prednisone—psoriasis	4.06e-05	0.000187	CcSEcCtD
Pentamidine—Headache—Prednisone—psoriasis	4.04e-05	0.000186	CcSEcCtD
Pentamidine—S100B—Immune System—TYK2—psoriasis	4.03e-05	0.000482	CbGpPWpGaD
Pentamidine—Hypersensitivity—Methotrexate—psoriasis	3.97e-05	0.000183	CcSEcCtD
Pentamidine—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.88e-05	0.000464	CbGpPWpGaD
Pentamidine—Asthenia—Methotrexate—psoriasis	3.87e-05	0.000178	CcSEcCtD
Pentamidine—CYP1A1—Metabolism—CYP2S1—psoriasis	3.85e-05	0.000461	CbGpPWpGaD
Pentamidine—Nausea—Prednisone—psoriasis	3.83e-05	0.000177	CcSEcCtD
Pentamidine—Pruritus—Methotrexate—psoriasis	3.81e-05	0.000176	CcSEcCtD
Pentamidine—S100B—Immune System—IFNG—psoriasis	3.77e-05	0.000451	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism—NDUFA5—psoriasis	3.71e-05	0.000444	CbGpPWpGaD
Pentamidine—Diarrhoea—Methotrexate—psoriasis	3.69e-05	0.00017	CcSEcCtD
Pentamidine—S100B—Immune System—CD4—psoriasis	3.64e-05	0.000436	CbGpPWpGaD
Pentamidine—Dizziness—Methotrexate—psoriasis	3.56e-05	0.000164	CcSEcCtD
Pentamidine—CYP2C8—Metabolism—CYP2S1—psoriasis	3.53e-05	0.000423	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.46e-05	0.000414	CbGpPWpGaD
Pentamidine—Vomiting—Methotrexate—psoriasis	3.43e-05	0.000158	CcSEcCtD
Pentamidine—S100B—Signaling Pathways—APOE—psoriasis	3.41e-05	0.000408	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—LEP—psoriasis	3.41e-05	0.000408	CbGpPWpGaD
Pentamidine—CYP2D6—Metabolism—NDUFA5—psoriasis	3.41e-05	0.000408	CbGpPWpGaD
Pentamidine—Rash—Methotrexate—psoriasis	3.4e-05	0.000157	CcSEcCtD
Pentamidine—Dermatitis—Methotrexate—psoriasis	3.4e-05	0.000156	CcSEcCtD
Pentamidine—S100B—Innate Immune System—IL6—psoriasis	3.38e-05	0.000405	CbGpPWpGaD
Pentamidine—Headache—Methotrexate—psoriasis	3.38e-05	0.000156	CcSEcCtD
Pentamidine—S100B—Immune System—JUN—psoriasis	3.26e-05	0.00039	CbGpPWpGaD
Pentamidine—Nausea—Methotrexate—psoriasis	3.2e-05	0.000148	CcSEcCtD
Pentamidine—S100B—Signaling Pathways—NFKBIA—psoriasis	3.18e-05	0.00038	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism—CYP2S1—psoriasis	3.15e-05	0.000377	CbGpPWpGaD
Pentamidine—S100B—Immune System—NFKB1—psoriasis	3.14e-05	0.000376	CbGpPWpGaD
Pentamidine—CYP4A11—Metabolism—CAT—psoriasis	2.92e-05	0.000349	CbGpPWpGaD
Pentamidine—CYP2D6—Metabolism—CYP2S1—psoriasis	2.9e-05	0.000347	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism—NDUFA5—psoriasis	2.89e-05	0.000346	CbGpPWpGaD
Pentamidine—S100B—Immune System—STAT3—psoriasis	2.82e-05	0.000338	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.7e-05	0.000322	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—TYK2—psoriasis	2.6e-05	0.000312	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism—CYP2S1—psoriasis	2.46e-05	0.000294	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—CXCL8—psoriasis	2.27e-05	0.000271	CbGpPWpGaD
Pentamidine—CYP4A11—Metabolism—APOE—psoriasis	2.27e-05	0.000271	CbGpPWpGaD
Pentamidine—CYP3A4—Metabolism—NDUFA5—psoriasis	2.23e-05	0.000267	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—JUN—psoriasis	2.11e-05	0.000252	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—NFKB1—psoriasis	2.03e-05	0.000243	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.02e-05	0.000242	CbGpPWpGaD
Pentamidine—CYP3A5—Metabolism—CARM1—psoriasis	1.99e-05	0.000238	CbGpPWpGaD
Pentamidine—CYP4A11—Metabolism—PPARG—psoriasis	1.97e-05	0.000236	CbGpPWpGaD
Pentamidine—S100B—Immune System—IL6—psoriasis	1.97e-05	0.000236	CbGpPWpGaD
Pentamidine—CYP3A4—Metabolism—CYP2S1—psoriasis	1.9e-05	0.000227	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism—CARM1—psoriasis	1.88e-05	0.000225	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.85e-05	0.000222	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—VEGFA—psoriasis	1.84e-05	0.00022	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—STAT3—psoriasis	1.82e-05	0.000218	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.76e-05	0.000211	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism—CARM1—psoriasis	1.73e-05	0.000207	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.65e-05	0.000198	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.61e-05	0.000193	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism—CARM1—psoriasis	1.54e-05	0.000184	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.44e-05	0.000172	CbGpPWpGaD
Pentamidine—CYP2D6—Metabolism—CARM1—psoriasis	1.42e-05	0.00017	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—TP53—psoriasis	1.39e-05	0.000167	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.29e-05	0.000154	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—IL6—psoriasis	1.27e-05	0.000152	CbGpPWpGaD
Pentamidine—CYP3A5—Metabolism—CAT—psoriasis	1.23e-05	0.000147	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism—CARM1—psoriasis	1.2e-05	0.000144	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism—CAT—psoriasis	1.16e-05	0.000139	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.12e-05	0.000134	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism—CAT—psoriasis	1.06e-05	0.000127	CbGpPWpGaD
Pentamidine—CYP3A5—Metabolism—APOE—psoriasis	9.52e-06	0.000114	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism—CAT—psoriasis	9.47e-06	0.000113	CbGpPWpGaD
Pentamidine—CYP3A4—Metabolism—CARM1—psoriasis	9.26e-06	0.000111	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism—APOE—psoriasis	9e-06	0.000108	CbGpPWpGaD
Pentamidine—CYP2D6—Metabolism—CAT—psoriasis	8.71e-06	0.000104	CbGpPWpGaD
Pentamidine—CYP3A5—Metabolism—PPARG—psoriasis	8.29e-06	9.92e-05	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism—APOE—psoriasis	8.25e-06	9.87e-05	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism—PPARG—psoriasis	7.84e-06	9.38e-05	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism—CAT—psoriasis	7.38e-06	8.83e-05	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism—APOE—psoriasis	7.36e-06	8.81e-05	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism—PPARG—psoriasis	7.18e-06	8.6e-05	CbGpPWpGaD
Pentamidine—CYP2D6—Metabolism—APOE—psoriasis	6.77e-06	8.1e-05	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism—PPARG—psoriasis	6.41e-06	7.67e-05	CbGpPWpGaD
Pentamidine—CYP2D6—Metabolism—PPARG—psoriasis	5.9e-06	7.06e-05	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism—APOE—psoriasis	5.74e-06	6.86e-05	CbGpPWpGaD
Pentamidine—CYP3A4—Metabolism—CAT—psoriasis	5.7e-06	6.82e-05	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism—PPARG—psoriasis	5e-06	5.98e-05	CbGpPWpGaD
Pentamidine—CYP3A4—Metabolism—APOE—psoriasis	4.43e-06	5.3e-05	CbGpPWpGaD
Pentamidine—CYP3A4—Metabolism—PPARG—psoriasis	3.86e-06	4.61e-05	CbGpPWpGaD
